BR112018075221B1 - Micropartículas compreendendo um composto contendo enxofre - Google Patents
Micropartículas compreendendo um composto contendo enxofre Download PDFInfo
- Publication number
- BR112018075221B1 BR112018075221B1 BR112018075221-5A BR112018075221A BR112018075221B1 BR 112018075221 B1 BR112018075221 B1 BR 112018075221B1 BR 112018075221 A BR112018075221 A BR 112018075221A BR 112018075221 B1 BR112018075221 B1 BR 112018075221B1
- Authority
- BR
- Brazil
- Prior art keywords
- microparticles
- cysteamine
- fact
- ethylamine
- particle size
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Accessories For Mixers (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346969P | 2016-06-07 | 2016-06-07 | |
| GBGB1609940.0A GB201609940D0 (en) | 2016-06-07 | 2016-06-07 | Microparticles |
| GB1609940.0 | 2016-06-07 | ||
| US62/346,969 | 2016-06-07 | ||
| PCT/GB2017/051637 WO2017212249A1 (en) | 2016-06-07 | 2017-06-06 | Microparticles comprising a sulphur-containing compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018075221A2 BR112018075221A2 (pt) | 2019-03-19 |
| BR112018075221B1 true BR112018075221B1 (pt) | 2024-02-06 |
Family
ID=56508202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075221-5A BR112018075221B1 (pt) | 2016-06-07 | 2017-06-06 | Micropartículas compreendendo um composto contendo enxofre |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11369568B2 (enExample) |
| EP (1) | EP3463325B1 (enExample) |
| JP (1) | JP7195934B2 (enExample) |
| KR (1) | KR102412212B1 (enExample) |
| CN (1) | CN109310654A (enExample) |
| AU (1) | AU2017277897B2 (enExample) |
| BR (1) | BR112018075221B1 (enExample) |
| CA (2) | CA3096121C (enExample) |
| DK (1) | DK3463325T3 (enExample) |
| ES (1) | ES2965017T3 (enExample) |
| FI (1) | FI3463325T3 (enExample) |
| GB (1) | GB201609940D0 (enExample) |
| MX (1) | MX2018014278A (enExample) |
| SG (1) | SG11201810934TA (enExample) |
| WO (1) | WO2017212249A1 (enExample) |
| ZA (1) | ZA201807852B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
| EP3572068A1 (en) * | 2018-05-22 | 2019-11-27 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | New salt of cysteamine for the preparation of highly respirable particles |
| CA3116637A1 (en) * | 2018-10-17 | 2020-04-23 | Novabiotics Limited | Dosage regime |
| US20230346696A1 (en) * | 2020-09-03 | 2023-11-02 | Philip Morris Products S.A. | Spray dried low hygroscopicity active powder compositions |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| JP2024545086A (ja) * | 2021-12-07 | 2024-12-05 | シラ セラピューティック インコーポレイティッド | 抗ウイルス治療剤及びその使用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8901570D0 (sv) | 1989-05-02 | 1989-05-02 | Draco Ab | Organic salts of cysteine derivatives |
| WO2006071102A1 (en) * | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
| AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| KR101433152B1 (ko) | 2006-12-22 | 2014-08-22 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 안과용 약물의 전달에 유용한 젤 |
| CN101342155B (zh) * | 2007-07-11 | 2012-01-04 | 天津帝士力投资控股集团有限公司 | 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法 |
| US20120135969A1 (en) | 2008-11-27 | 2012-05-31 | Boehringer Ingelheim International Gmbh | Novel powdered crystalline medicines for inhalation |
| CA2751386C (en) * | 2009-02-03 | 2018-03-06 | Microbion Corporation | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| WO2010138419A2 (en) | 2009-05-23 | 2010-12-02 | Obio Pharmaceutical (H.K.) Ltd. | Materials and methods for treating viral infections |
| GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| CA2981038C (en) | 2011-05-19 | 2018-09-25 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
| JP5981123B2 (ja) * | 2011-10-11 | 2016-08-31 | サンサ コーポレーション （バルバドス） インク | ニコチン薬の製造法およびその方法により製造される医薬 |
| AU2011379972B2 (en) * | 2011-10-26 | 2016-05-12 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| JP2015509489A (ja) * | 2012-02-10 | 2015-03-30 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | がんの処置のためのグリシン開裂系の阻害 |
| ITMI20130572A1 (it) | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
| JP6483714B2 (ja) * | 2013-10-11 | 2019-03-13 | ローレンス エス． ジスマン， | 噴霧乾燥製剤 |
| GB201416716D0 (en) | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| ITUA20161799A1 (it) * | 2016-03-18 | 2017-09-18 | Recordati Ind Chimica E Farmaceutica S P A | Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale |
| US10905660B2 (en) * | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
-
2016
- 2016-06-07 GB GBGB1609940.0A patent/GB201609940D0/en not_active Ceased
-
2017
- 2017-06-06 KR KR1020187035476A patent/KR102412212B1/ko active Active
- 2017-06-06 EP EP17735616.9A patent/EP3463325B1/en active Active
- 2017-06-06 WO PCT/GB2017/051637 patent/WO2017212249A1/en not_active Ceased
- 2017-06-06 CA CA3096121A patent/CA3096121C/en active Active
- 2017-06-06 SG SG11201810934TA patent/SG11201810934TA/en unknown
- 2017-06-06 JP JP2018563831A patent/JP7195934B2/ja active Active
- 2017-06-06 FI FIEP17735616.9T patent/FI3463325T3/fi active
- 2017-06-06 CN CN201780035360.7A patent/CN109310654A/zh active Pending
- 2017-06-06 DK DK17735616.9T patent/DK3463325T3/da active
- 2017-06-06 US US16/307,990 patent/US11369568B2/en active Active
- 2017-06-06 BR BR112018075221-5A patent/BR112018075221B1/pt active IP Right Grant
- 2017-06-06 CA CA3026743A patent/CA3026743C/en active Active
- 2017-06-06 MX MX2018014278A patent/MX2018014278A/es unknown
- 2017-06-06 ES ES17735616T patent/ES2965017T3/es active Active
- 2017-06-06 AU AU2017277897A patent/AU2017277897B2/en active Active
-
2018
- 2018-11-21 ZA ZA2018/07852A patent/ZA201807852B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7195934B2 (ja) | 2022-12-26 |
| EP3463325B1 (en) | 2023-11-08 |
| WO2017212249A1 (en) | 2017-12-14 |
| CA3096121A1 (en) | 2017-12-14 |
| MX2018014278A (es) | 2019-03-14 |
| GB201609940D0 (en) | 2016-07-20 |
| ZA201807852B (en) | 2023-05-31 |
| SG11201810934TA (en) | 2019-01-30 |
| US20190175501A1 (en) | 2019-06-13 |
| KR102412212B1 (ko) | 2022-06-23 |
| US11369568B2 (en) | 2022-06-28 |
| EP3463325A1 (en) | 2019-04-10 |
| RU2018142841A (ru) | 2020-06-04 |
| RU2018142841A3 (enExample) | 2020-09-30 |
| CA3026743A1 (en) | 2017-12-14 |
| ES2965017T3 (es) | 2024-04-10 |
| FI3463325T3 (fi) | 2023-12-19 |
| JP2019517541A (ja) | 2019-06-24 |
| DK3463325T3 (da) | 2024-01-02 |
| CA3026743C (en) | 2024-05-28 |
| KR20190016957A (ko) | 2019-02-19 |
| CA3096121C (en) | 2022-11-15 |
| CN109310654A (zh) | 2019-02-05 |
| BR112018075221A2 (pt) | 2019-03-19 |
| AU2017277897B2 (en) | 2022-09-08 |
| AU2017277897A1 (en) | 2018-12-20 |
| NZ748596A (en) | 2025-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10905660B2 (en) | Microparticles | |
| US11369568B2 (en) | Microparticles comprising a sulphur-containing compound | |
| ES2899621T3 (es) | Polvos secos catiónicos que comprenden sal de magnesio | |
| ES2406405T3 (es) | Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares | |
| ES2379775T3 (es) | Formulaciones farmacéuticas y métodos para tratar infecciones del aparato respiratorio | |
| CA2981038C (en) | Dry powder vancomycin compositions and associated methods | |
| BR112013007304B1 (pt) | Pós secos de cátion de metal monovalente para inalação | |
| BRPI1011721B1 (pt) | Formulações em pó seco inaláveis compreendendo sal de cátion de metal divalente e métodos para tratar doenças pulmonares | |
| Manniello et al. | Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility | |
| CN102448439A (zh) | 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物 | |
| JP2012522009A (ja) | 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法 | |
| CA2809666A1 (en) | Dry powder formulations and methods for treating pulmonary diseases | |
| AU2012254999A1 (en) | Dry powder vancomycin compositions and associated methods | |
| PT1594500E (pt) | Tratamento para doenças bacterianas dos órgãos respiratórios por aplicação local de fluoroquinolonas | |
| US9572774B2 (en) | Dry powder vancomycin compositions and associated methods | |
| Saha et al. | Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections | |
| RU2780397C2 (ru) | Микрочастицы, содержащие серосодержащие соединения | |
| ES2918193T3 (es) | Polvo medicamentoso para administración por inhalación y un proceso del mismo | |
| Adhikari et al. | Co-amorphization: a formulation strategy for amorphous high dose dry powder to treat lung infections | |
| IL263540B2 (en) | Microparticles that include a sulfur-containing compound | |
| Gadgil | A comparative study between high potency dry powder inhalation and nebulized solution of vancomycin hydrochloride for lung delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2017, OBSERVADAS AS CONDICOES LEGAIS |